Answers are grounded in this paper and cite their sources.
Ulcerative colitis (UC) is a global chronic relapsing inflammatory bowel disease characterized by continuous colonic mucosal inflammation, with very limited safe, effective, and sustainable long-term oral intervention strategies for its routine clinical management. Herein, a novel edible hydrogel was fabricated using riclin, a food-derived succinoglycan polysaccharide, via food-grade sodium trimetaphosphate cross-linking, with 4% (w/v) riclin hydrogel (Ric-gel) optimized for its uniform porous structure, excellent injectability, and pH-stable colon-targeted delivery with potential microbiota-dependent release properties. Ric-gel exerted superior protection against DSS-induced colitis relative to free riclin, improving clinical and histopathological outcomes. Mechanistically, Ric-gel modulated the gut microbiota and immunity. It reshaped gut microbial homeostasis to boost SCFA production, inhibited NF-κB-driven inflammation, rebalanced colonic Th1/Th2 immune homeostasis, and maintained mucosal barrier integrity via goblet cell recovery and elevated Muc2. Validated by in vitro and in vivo assays, Ric-gel exhibited favorable preliminary biocompatibility, highlighting its promise as a microbiome-targeted functional-food candidate for UC management.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: